Kestra Advisory Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Kestra Advisory Services’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,395	Closed	-$117K	–	3123
2025 Q4	$117K	Buy	+4,395	New	+$105K	﹤0.01%	3308
2023 Q3	–	Sell	-8,403	Closed	-$201K	–	2107
2023 Q2	$201K	Buy	+8,403	New	+$187K	﹤0.01%	1904
2022 Q2	–	Sell	-8,596	Closed	-$208K	–	2130
2022 Q1	$208K	Buy	+8,596	New	+$208K	﹤0.01%	1825
2021 Q4	–	Sell	-10,438	Closed	-$173K	–	2006
2021 Q3	$173K	Sell	10,438 -152	-1%	-$2.93K	﹤0.01%	1994
2021 Q2	$258K	Sell	10,590 -1,071	-9%	-$24.2K	﹤0.01%	1670
2021 Q1	$301K	Sell	11,661 -3,942	-25%	-$174K	﹤0.01%	1465
2020 Q4	$838K	Buy	15,603 +2,753	+21%	+$137K	0.01%	941
2020 Q3	$530K	Buy	+12,850	New	+$555K	0.01%	858

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Kestra Advisory Services's ACAD Position: Q1 2026 in Review

Kestra Advisory Services sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 4,395 shares — an estimated $117K sold.

Kestra Advisory Services first reported a position in ACAD in Q3 2020 and held it in 8 quarters. The position peaked at $838K in Q4 2020. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Kestra Advisory Services reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Kestra Advisory Services sold 4,395 Acadia Pharmaceuticals shares in Q1 2026, an estimated $117K.
Kestra Advisory Services first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 8 quarters.
Kestra Advisory Services's Acadia Pharmaceuticals position peaked at $838K in Q4 2020.
343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.